{"id":8978,"date":"2025-03-26T02:03:00","date_gmt":"2025-03-26T02:03:00","guid":{"rendered":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/"},"modified":"2025-03-26T02:03:00","modified_gmt":"2025-03-26T02:03:00","slug":"%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4","status":"publish","type":"post","link":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/","title":{"rendered":"\u3010AACR 2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e94\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55"},"content":{"rendered":"<p><span class=\"legendSpanClass\">\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde<\/span><span class=\"legendSpanClass\">2025\u5e743\u670826\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u8840\u6db2\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u5171\u6709\u4e94\u9879\u4e34\u5e8a\u524d\u7814\u7a76\u8fdb\u5c55\u5165\u90092025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u3002\u6b64\u6b21\u4f1a\u8bae\u5c06\u4e8e 2025 \u5e74 4 \u6708 25 \u65e5\u81f3 30 \u65e5\u5728\u7f8e\u56fd\u829d\u52a0\u54e5\u4e3e\u884c\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p>\n                        <a href=\"https:\/\/mma.prnewswire.com\/media\/891219\/Ascentage_Pharma_Logo.html\" target=\"_blank\" rel=\"noopener\"><\/a><\/p>\n<p>                        \n                <\/p>\n<\/div>\n<p>\u672c\u6b21\u5c06\u8981\u5c55\u793a\u7684\u6570\u636e\u6d89\u53ca\u516c\u53f8\u4e94\u4e2a\u54c1\u79cd\uff0c\u5305\u62ec\uff1a\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aHQP1351\uff09\u3001Bcl-2\u6291\u5236\u5242APG-2575\u3001FAK\/ALK\/ROS1\u4e09\u8054\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242APG-2449\u3001\u80da\u80ce\u5916\u80da\u5c42\u53d1\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5242APG-5918\u4ee5\u53caIAP\u62ee\u6297\u5242AS03157\u3002<\/p>\n<p>AACR\u5e74\u4f1a\u662f\u63a8\u52a8\u6297\u80bf\u7624\u4e8b\u4e1a\u53d1\u5c55\u7684\u91cd\u8981\u5e73\u53f0\uff0c\u79d1\u5b66\u5bb6\u3001\u4e34\u5e8a\u533b\u751f\u3001\u533b\u7597\u5de5\u4f5c\u8005\u3001\u764c\u75c7\u5e78\u5b58\u8005\u3001\u60a3\u8005\u53ca\u5021\u5bfc\u8005\u6bcf\u5e74\u9f50\u805a\u4e00\u5802\uff0c\u5206\u4eab\u548c\u63a2\u8ba8\u6297\u80bf\u7624\u6700\u65b0\u7a81\u7834\u3002\u4ece\u7fa4\u4f53\u79d1\u5b66\u4e0e\u9884\u9632\uff0c\u5230\u764c\u75c7\u751f\u7269\u5b66\u3001\u8f6c\u5316\u533b\u5b66\u4e0e\u4e34\u5e8a\u7814\u7a76\uff0c\u518d\u5230\u5e78\u5b58\u8005\u5173\u6000\u4e0e\u6743\u76ca\u5021\u5bfc\uff0cAACR \u5e74\u4f1a\u5168\u65b9\u4f4d\u5c55\u793a\u4e86\u524d\u6cbf\u7684\u764c\u75c7\u79d1\u5b66\u4e0e\u533b\u5b66\u6210\u679c\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u4e94\u9879\u4e34\u5e8a\u524d\u7814\u7a76\u7684\u6458\u8981\u4fe1\u606f\u5982\u4e0b\uff1a<\/p>\n<p>Olverembatinib (HQP1351) in combination with lisaftoclax (APG-2575) overcomes venetoclax resistance in preclinical models of acute myeloid leukemia (AML)<\/p>\n<p>\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408APG-2575\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u7ef4\u5948\u514b\u62c9\u8010\u836f<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a5652\u5206\u4f1a\u573a\u7c7b\u522b\uff1a\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\u5206\u4f1a\u573a\u6807\u9898\uff1a\u65b0\u578b\u6297\u80bf\u7624\u836f\u72693\u5c55\u793a\u65f6\u95f4\uff1a<\/p>\n<p>\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092025\u5e744\u670829\u65e5\uff0c\u5468\u4e8c\uff0c\u4e0b\u534814:00 &#8211; 17:00<\/p>\n<p>\uff08\u5317\u4eac\u65f6\u95f4\uff092025\u5e744\u670830\u65e5\uff0c\u5468\u4e09\uff0c\u51cc\u66683:00 \u2013 6:00<\/p>\n<p>Effects of olverembatinib (HQP1351) in combination with BCL-2 inhibitor lisaftoclax (APG-2575) in T-cell acute lymphoblastic leukemia (T\u2011ALL)<\/p>\n<p>\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408Bcl-2\u6291\u5236\u5242APG-2575\u5728 T \u7ec6\u80de\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08T-ALL\uff09\u4e2d\u7684\u6548\u679c<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a5648\u5206\u4f1a\u573a\u7c7b\u522b\uff1a\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\u5206\u4f1a\u573a\u6807\u9898\uff1a\u65b0\u578b\u6297\u80bf\u7624\u836f\u72693\u5c55\u793a\u65f6\u95f4\uff1a<\/p>\n<p>\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092025\u5e744\u670829\u65e5\uff0c\u5468\u4e8c\uff0c\u4e0b\u534814:00 &#8211; 17:00<\/p>\n<p>\uff08\u5317\u4eac\u65f6\u95f4\uff092025\u5e744\u670830\u65e5\uff0c\u5468\u4e09\uff0c\u51cc\u66683:00 \u2013 6:00<\/p>\n<p>Embryonic ectoderm development protein (EED) inhibitor APG-5918 exhibits potent antitumor activity and synergizes with androgen receptor (AR) inhibitor enzalutamide in preclinical prostate cancer (PCa) models<\/p>\n<p>\u80da\u80ce\u5916\u80da\u5c42\u53d1\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5242APG-5918\u5728\u524d\u5217\u817a\u764c\uff08PCa\uff09\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u53ca\u5176\u4e0e\u96c4\u6fc0\u7d20\u53d7\u4f53\uff08AR\uff09\u6291\u5236\u5242\u6069\u624e\u5362\u80fa\u7684\u534f\u540c\u4f5c\u7528\u7814\u7a76<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a446\u5206\u4f1a\u573a\u7c7b\u522b\uff1a\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\u5206\u4f1a\u573a\u6807\u9898\uff1a\u8868\u89c2\u9057\u4f20\u5b66\u9776\u70b9\u5c55\u793a\u65f6\u95f4\uff1a<\/p>\n<p>\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092025\u5e744\u670827\u65e5\uff0c\u5468\u65e5\uff0c\u4e0b\u534814:00 &#8211; 17:00<\/p>\n<p>\uff08\u5317\u4eac\u65f6\u95f4\uff092025\u5e744\u670828\u65e5\uff0c\u5468\u4e00\uff0c\u51cc\u66683:00 &#8211; 6:00<\/p>\n<p>APG-2449, a novel focal adhesion kinase (FAK) inhibitor, enhances the antitumor activity of chemotherapy in preclinical models of small-cell lung cancer (SCLC) with activated FAK<\/p>\n<p>\u65b0\u578b\u9ecf\u7740\u6591\u6fc0\u9176\uff08FAK\uff09\u6291\u5236\u5242APG-2449\u53ef\u589e\u5f3a\u5316\u7597\u5728FAK\u6d3b\u5316\u7684\u5c0f\u7ec6\u80de\u80ba\u764c\uff08SCLC\uff09\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u6297\u80bf\u7624\u6d3b\u6027<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a1679\u5206\u4f1a\u573a\u7c7b\u522b\uff1a\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\u5206\u4f1a\u573a\u6807\u9898\uff1a\u764c\u75c7\u6cbb\u7597\u7684\u8054\u5408\u7528\u836f\u7b56\u7565\u5c55\u793a\u65f6\u95f4\uff1a<\/p>\n<p>\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092025\u5e744\u670828\u65e5\uff0c\u5468\u4e00\uff0c\u4e0a\u53489:00 &#8211; 12:00<\/p>\n<p>\uff08\u5317\u4eac\u65f6\u95f4\uff092025\u5e744\u670828\u65e5\uff0c\u5468\u4e00\uff0c\u665a\u4e0a22:00 \u2013 \u6b21\u65e5\u51cc\u66681:00<\/p>\n<p>Discovery of AS03157 as a highly potent and orally active antagonist of inhibitor of apoptosis proteins (IAPs)<\/p>\n<p>\u4e00\u79cd\u9ad8\u6548\u53e3\u670d\u6297\u51cb\u4ea1\u86cb\u767d\u62ee\u6297\u5242AS03157\u7684\u53d1\u73b0<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a5651\u5206\u4f1a\u573a\u7c7b\u522b\uff1a\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\u5206\u4f1a\u573a\u6807\u9898\uff1a\u65b0\u578b\u6297\u80bf\u7624\u836f\u72693\u5c55\u793a\u65f6\u95f4\uff1a<\/p>\n<p>\uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092025\u5e744\u670829\u65e5\uff0c\u5468\u4e8c\uff0c\u4e0b\u534814:00 &#8211; 17:00<\/p>\n<p>\uff08\u5317\u4eac\u65f6\u95f4\uff092025\u5e744\u670830\u65e5\uff0c\u5468\u4e09\uff0c\u51cc\u66683:00 &#8211; 6:00<\/p>\n<p>\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7efc\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u7814\u53d1\u521b\u65b0\u836f\uff0c\u4ee5\u89e3\u51b3\u80bf\u7624\u7b49\u9886\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u56fd\u7eb3\u65af\u8fbe\u514b\u8bc1\u5238\u4ea4\u6613\u6240\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1aAAPG\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u5df2\u5efa\u7acb\u4e30\u5bcc\u7684\u521b\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c\u00a0MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u5df2\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5540\u591a\u9879\u4e34\u5e8a\u8bd5\u9a8c\uff0c \u5305\u62ec\u6d89\u53ca\u4e3b\u8981\u54c1\u79cd\u768411\u9879\u7f8e\u56fd\/\u5168\u7403\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\uff08\u5df2\u5b8c\u6210\/\u8fdb\u884c\u4e2d\uff09\uff0c\u5176\u4e2d2\u9879\u6ce8\u518cIII\u671f\u7814\u7a76\u83b7FDA\u8bb8\u53ef\u3002<\/p>\n<p>\u516c\u53f8\u6838\u5fc3\u54c1\u79cd\u8010\u7acb\u514b\u00ae\u5df2\u5728\u4e2d\u56fd\u83b7\u6279\u4e0a\u5e02\uff0c\u4e14\u83b7\u6279\u9002\u5e94\u75c7\u5747\u88ab\u6210\u529f\u7eb3\u5165\u56fd\u5bb6\u533b\u4fdd\u836f\u54c1\u76ee\u5f55\u3002\u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u79cd\uff0c\u65b0\u578bBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242APG-2575\uff08Lisaftoclax\uff09\u7684\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\uff08NDA\uff09\u5df2\u83b7CDE\u53d7\u7406\uff0c\u5e76\u88ab\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u3002<\/p>\n<p>\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u4e2a\u5728\u7814\u65b0\u836f\u5171\u83b716\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c2\u9879FDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u4ee5\u53ca2\u9879FDA\u513f\u7ae5\u7f55\u89c1\u75c5\u8d44\u683c\u8ba4\u8bc1\u3002\u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0e\u6b66\u7530\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u3001\u4fe1\u8fbe\u7b49\u9886\u5148\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u56fd\u56fd\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b66\u7b49\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u5df2\u5728\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u9886\u57df\u5efa\u7acb\u7ecf\u9a8c\u4e30\u5bcc\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u4e0e\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c&#8221;\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42&#8221;\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n<p>\u524d\u77bb\u6027\u58f0\u660e<\/p>\n<p>\u672c\u65b0\u95fb\u7a3f\u5305\u542b\u6839\u636e\u7f8e\u56fd\u300a1995\u5e74\u79c1\u4eba\u8bc1\u5238\u8bc9\u8bbc\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7ecf\u4fee\u8ba2\u7684\u300a1933\u5e74\u8bc1\u5238\u6cd5\u300b\u7b2c27A\u6761\u548c\u300a1934\u5e74\u8bc1\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u6761\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9648\u8ff0\u3002\u9664\u5386\u53f2\u4e8b\u5b9e\u9648\u8ff0\u5916\uff0c\u672c\u65b0\u95fb\u7a3f\u4e2d\u7684\u6240\u6709\u5185\u5bb9\u5747\u53ef\u80fd\u6784\u6210\u524d\u77bb\u6027\u9648\u8ff0\uff0c\u5305\u62ec\u4e9a\u76db\u533b\u836f\u5bf9\u672a\u6765\u4e8b\u4ef6\u3001\u7ecf\u8425\u6210\u679c\u6216\u8d22\u52a1\u72b6\u51b5\u6240\u53d1\u8868\u7684\u610f\u89c1\u3001\u9884\u671f\u3001\u4fe1\u5ff5\u3001\u8ba1\u5212\u3001\u76ee\u6807\u3001\u5047\u8bbe\u6216\u9884\u6d4b\u3002<\/p>\n<p>\u8fd9\u4e9b\u524d\u77bb\u6027\u9648\u8ff0\u53d7\u5230\u8bf8\u591a\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u7684\u5f71\u54cd\uff0c\u5177\u4f53\u5185\u5bb9\u5df2\u5728\u4e9a\u76db\u533b\u836f\u5411\u7f8e\u56fd\u8bc1\u5238\u4ea4\u6613\u59d4\u5458\u4f1a\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8be6\u7ec6\u8bf4\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7ecf\u4fee\u8ba2\u7684F-1\u8868\u683c\u6ce8\u518c\u8bf4\u660e\u4e66\u4e2d\u7684&#8221;\u98ce\u9669\u56e0\u7d20&#8221;\u548c&#8221;\u5173\u4e8e\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u884c\u4e1a\u6570\u636e\u7684\u7279\u522b\u8bf4\u660e&#8221;\u7ae0\u8282\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u53d1\u884c\u4e0a\u5e02\u62db\u80a1\u4e66\u4e2d\u7684&#8221;\u524d\u77bb\u6027\u58f0\u660e&#8221;\u3001&#8221;\u98ce\u9669\u56e0\u7d20&#8221;\u7ae0\u8282\uff0c\u4ee5\u53ca\u6211\u4eec\u4e0d\u65f6\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u8fd9\u4e9b\u56e0\u7d20\u53ef\u80fd\u5bfc\u81f4\u5b9e\u9645\u4e1a\u7ee9\u3001\u8fd0\u8425\u6c34\u5e73\u3001\u7ecf\u8425\u6210\u679c\u6216\u6210\u5c31\u4e0e\u524d\u77bb\u6027\u9648\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u5f02\u3002\u672c\u524d\u77bb\u6027\u58f0\u660e\u4e2d\u7684\u9648\u8ff0\u4e0d\u6784\u6210\u516c\u53f8\u7ba1\u7406\u5c42\u7684\u5229\u6da6\u9884\u6d4b\u3002<\/p>\n<p>\u56e0\u6b64\uff0c\u8be5\u7b49\u524d\u77bb\u6027\u9648\u8ff0\u4e0d\u5e94\u88ab\u89c6\u4e3a\u5bf9\u672a\u6765\u4e8b\u4ef6\u7684\u9884\u6d4b\u3002\u672c\u65b0\u95fb\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u57fa\u4e8e\u4e9a\u76db\u533b\u836f\u5f53\u524d\u5bf9\u672a\u6765\u53d1\u5c55\u53ca\u5176\u6f5c\u5728\u5f71\u54cd\u7684\u9884\u671f\u548c\u5224\u65ad\uff0c\u4e14\u4ec5\u4ee3\u8868\u622a\u81f3\u9648\u8ff0\u53d1\u8868\u4e4b\u65e5\u7684\u89c2\u70b9\u3002\u65e0\u8bba\u51fa\u73b0\u65b0\u4fe1\u606f\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u4e9a\u76db\u533b\u836f\u5747\u65e0\u4e49\u52a1\u66f4\u65b0\u6216\u4fee\u8ba2\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u3002<\/p>\n<p>SOURCE  \u4e9a\u76db\u533b\u836f<\/p>","protected":false},"excerpt":{"rendered":"<p>\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2025\u5e743\u670826\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u8840\u6db2\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u5171\u6709\u4e94\u9879\u4e34\u5e8a\u524d\u7814\u7a76\u8fdb\u5c55\u5165\u90092025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u3002\u6b64\u6b21\u4f1a\u8bae\u5c06\u4e8e 2025 \u5e74 4 \u6708 25 \u65e5\u81f3 30 \u65e5\u5728\u7f8e\u56fd\u829d\u52a0\u54e5\u4e3e\u884c\u3002 \u672c\u6b21\u5c06\u8981\u5c55\u793a\u7684\u6570\u636e\u6d89\u53ca\u516c\u53f8\u4e94\u4e2a\u54c1\u79cd\uff0c\u5305\u62ec\uff1a\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aHQP1351\uff09\u3001Bcl-2\u6291\u5236\u5242APG-2575\u3001FAK\/ALK\/ROS1\u4e09\u8054\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242APG-2449\u3001\u80da\u80ce\u5916\u80da\u5c42\u53d1\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5242APG-5918\u4ee5\u53caIAP\u62ee\u6297\u5242AS03157\u3002 AACR\u5e74\u4f1a\u662f\u63a8\u52a8\u6297\u80bf\u7624\u4e8b\u4e1a\u53d1\u5c55\u7684\u91cd\u8981\u5e73\u53f0\uff0c\u79d1\u5b66\u5bb6\u3001\u4e34\u5e8a\u533b\u751f\u3001\u533b\u7597\u5de5\u4f5c\u8005\u3001\u764c\u75c7\u5e78\u5b58\u8005\u3001\u60a3\u8005\u53ca\u5021\u5bfc\u8005\u6bcf\u5e74\u9f50\u805a\u4e00\u5802\uff0c\u5206\u4eab\u548c\u63a2\u8ba8\u6297\u80bf\u7624\u6700\u65b0\u7a81\u7834\u3002\u4ece\u7fa4\u4f53\u79d1\u5b66\u4e0e\u9884\u9632\uff0c\u5230\u764c\u75c7\u751f\u7269\u5b66\u3001\u8f6c\u5316\u533b\u5b66\u4e0e\u4e34\u5e8a\u7814\u7a76\uff0c\u518d\u5230\u5e78\u5b58\u8005\u5173\u6000\u4e0e\u6743\u76ca\u5021\u5bfc\uff0cAACR \u5e74\u4f1a\u5168\u65b9\u4f4d\u5c55\u793a\u4e86\u524d\u6cbf\u7684\u764c\u75c7\u79d1\u5b66\u4e0e\u533b\u5b66\u6210\u679c\u3002 \u4e9a\u76db\u533b\u836f\u4e94\u9879\u4e34\u5e8a\u524d\u7814\u7a76\u7684\u6458\u8981\u4fe1\u606f\u5982\u4e0b\uff1a Olverembatinib (HQP1351) in combination with lisaftoclax (APG-2575) overcomes venetoclax resistance in preclinical models of acute myeloid leukemia (AML) \u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408APG-2575\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u7ef4\u5948\u514b\u62c9\u8010\u836f \u6458\u8981\u7f16\u53f7\uff1a5652\u5206\u4f1a\u573a\u7c7b\u522b\uff1a\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\u5206\u4f1a\u573a\u6807\u9898\uff1a\u65b0\u578b\u6297\u80bf\u7624\u836f\u72693\u5c55\u793a\u65f6\u95f4\uff1a \uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092025\u5e744\u670829\u65e5\uff0c\u5468\u4e8c\uff0c\u4e0b\u534814:00 &#8211; 17:00 \uff08\u5317\u4eac\u65f6\u95f4\uff092025\u5e744\u670830\u65e5\uff0c\u5468\u4e09\uff0c\u51cc\u66683:00 \u2013 6:00 Effects of olverembatinib (HQP1351) in combination with BCL-2 inhibitor lisaftoclax (APG-2575) in T-cell [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":8979,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-8978","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u3010AACR 2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e94\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55 - Money Compass CN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/moneycompass.com.my\/cn\/\u3010aacr-2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u3010AACR 2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e94\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55 - Money Compass CN\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2025\u5e743\u670826\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u8840\u6db2\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u5171\u6709\u4e94\u9879\u4e34\u5e8a\u524d\u7814\u7a76\u8fdb\u5c55\u5165\u90092025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u3002\u6b64\u6b21\u4f1a\u8bae\u5c06\u4e8e 2025 \u5e74 4 \u6708 25 \u65e5\u81f3 30 \u65e5\u5728\u7f8e\u56fd\u829d\u52a0\u54e5\u4e3e\u884c\u3002 \u672c\u6b21\u5c06\u8981\u5c55\u793a\u7684\u6570\u636e\u6d89\u53ca\u516c\u53f8\u4e94\u4e2a\u54c1\u79cd\uff0c\u5305\u62ec\uff1a\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aHQP1351\uff09\u3001Bcl-2\u6291\u5236\u5242APG-2575\u3001FAK\/ALK\/ROS1\u4e09\u8054\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242APG-2449\u3001\u80da\u80ce\u5916\u80da\u5c42\u53d1\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5242APG-5918\u4ee5\u53caIAP\u62ee\u6297\u5242AS03157\u3002 AACR\u5e74\u4f1a\u662f\u63a8\u52a8\u6297\u80bf\u7624\u4e8b\u4e1a\u53d1\u5c55\u7684\u91cd\u8981\u5e73\u53f0\uff0c\u79d1\u5b66\u5bb6\u3001\u4e34\u5e8a\u533b\u751f\u3001\u533b\u7597\u5de5\u4f5c\u8005\u3001\u764c\u75c7\u5e78\u5b58\u8005\u3001\u60a3\u8005\u53ca\u5021\u5bfc\u8005\u6bcf\u5e74\u9f50\u805a\u4e00\u5802\uff0c\u5206\u4eab\u548c\u63a2\u8ba8\u6297\u80bf\u7624\u6700\u65b0\u7a81\u7834\u3002\u4ece\u7fa4\u4f53\u79d1\u5b66\u4e0e\u9884\u9632\uff0c\u5230\u764c\u75c7\u751f\u7269\u5b66\u3001\u8f6c\u5316\u533b\u5b66\u4e0e\u4e34\u5e8a\u7814\u7a76\uff0c\u518d\u5230\u5e78\u5b58\u8005\u5173\u6000\u4e0e\u6743\u76ca\u5021\u5bfc\uff0cAACR \u5e74\u4f1a\u5168\u65b9\u4f4d\u5c55\u793a\u4e86\u524d\u6cbf\u7684\u764c\u75c7\u79d1\u5b66\u4e0e\u533b\u5b66\u6210\u679c\u3002 \u4e9a\u76db\u533b\u836f\u4e94\u9879\u4e34\u5e8a\u524d\u7814\u7a76\u7684\u6458\u8981\u4fe1\u606f\u5982\u4e0b\uff1a Olverembatinib (HQP1351) in combination with lisaftoclax (APG-2575) overcomes venetoclax resistance in preclinical models of acute myeloid leukemia (AML) \u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408APG-2575\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u7ef4\u5948\u514b\u62c9\u8010\u836f \u6458\u8981\u7f16\u53f7\uff1a5652\u5206\u4f1a\u573a\u7c7b\u522b\uff1a\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\u5206\u4f1a\u573a\u6807\u9898\uff1a\u65b0\u578b\u6297\u80bf\u7624\u836f\u72693\u5c55\u793a\u65f6\u95f4\uff1a \uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092025\u5e744\u670829\u65e5\uff0c\u5468\u4e8c\uff0c\u4e0b\u534814:00 &#8211; 17:00 \uff08\u5317\u4eac\u65f6\u95f4\uff092025\u5e744\u670830\u65e5\uff0c\u5468\u4e09\uff0c\u51cc\u66683:00 \u2013 6:00 Effects of olverembatinib (HQP1351) in combination with BCL-2 inhibitor lisaftoclax (APG-2575) in T-cell [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/moneycompass.com.my\/cn\/\u3010aacr-2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\/\" \/>\n<meta property=\"og:site_name\" content=\"Money Compass CN\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T02:03:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/03\/Ascentage_Pharma_Logo-PpD9vJ.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"144\" \/>\n\t<meta property=\"og:image:height\" content=\"28\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/\",\"name\":\"\u3010AACR 2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e94\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55 - Money Compass CN\",\"isPartOf\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/03\/Ascentage_Pharma_Logo-PpD9vJ.jpeg\",\"datePublished\":\"2025-03-26T02:03:00+00:00\",\"dateModified\":\"2025-03-26T02:03:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#primaryimage\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/03\/Ascentage_Pharma_Logo-PpD9vJ.jpeg\",\"contentUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/03\/Ascentage_Pharma_Logo-PpD9vJ.jpeg\",\"width\":144,\"height\":28},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/moneycompass.com.my\/cn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u3010AACR 2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e94\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/\",\"name\":\"Money Compass CN\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u3010AACR 2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e94\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55 - Money Compass CN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/moneycompass.com.my\/cn\/\u3010aacr-2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\/","og_locale":"en_US","og_type":"article","og_title":"\u3010AACR 2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e94\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55 - Money Compass CN","og_description":"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2025\u5e743\u670826\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u8840\u6db2\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\u4ee3\u7801\uff1aAAPG\uff1b\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a6855\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u5171\u6709\u4e94\u9879\u4e34\u5e8a\u524d\u7814\u7a76\u8fdb\u5c55\u5165\u90092025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u3002\u6b64\u6b21\u4f1a\u8bae\u5c06\u4e8e 2025 \u5e74 4 \u6708 25 \u65e5\u81f3 30 \u65e5\u5728\u7f8e\u56fd\u829d\u52a0\u54e5\u4e3e\u884c\u3002 \u672c\u6b21\u5c06\u8981\u5c55\u793a\u7684\u6570\u636e\u6d89\u53ca\u516c\u53f8\u4e94\u4e2a\u54c1\u79cd\uff0c\u5305\u62ec\uff1a\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u53d1\u4ee3\u53f7\uff1aHQP1351\uff09\u3001Bcl-2\u6291\u5236\u5242APG-2575\u3001FAK\/ALK\/ROS1\u4e09\u8054\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242APG-2449\u3001\u80da\u80ce\u5916\u80da\u5c42\u53d1\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5242APG-5918\u4ee5\u53caIAP\u62ee\u6297\u5242AS03157\u3002 AACR\u5e74\u4f1a\u662f\u63a8\u52a8\u6297\u80bf\u7624\u4e8b\u4e1a\u53d1\u5c55\u7684\u91cd\u8981\u5e73\u53f0\uff0c\u79d1\u5b66\u5bb6\u3001\u4e34\u5e8a\u533b\u751f\u3001\u533b\u7597\u5de5\u4f5c\u8005\u3001\u764c\u75c7\u5e78\u5b58\u8005\u3001\u60a3\u8005\u53ca\u5021\u5bfc\u8005\u6bcf\u5e74\u9f50\u805a\u4e00\u5802\uff0c\u5206\u4eab\u548c\u63a2\u8ba8\u6297\u80bf\u7624\u6700\u65b0\u7a81\u7834\u3002\u4ece\u7fa4\u4f53\u79d1\u5b66\u4e0e\u9884\u9632\uff0c\u5230\u764c\u75c7\u751f\u7269\u5b66\u3001\u8f6c\u5316\u533b\u5b66\u4e0e\u4e34\u5e8a\u7814\u7a76\uff0c\u518d\u5230\u5e78\u5b58\u8005\u5173\u6000\u4e0e\u6743\u76ca\u5021\u5bfc\uff0cAACR \u5e74\u4f1a\u5168\u65b9\u4f4d\u5c55\u793a\u4e86\u524d\u6cbf\u7684\u764c\u75c7\u79d1\u5b66\u4e0e\u533b\u5b66\u6210\u679c\u3002 \u4e9a\u76db\u533b\u836f\u4e94\u9879\u4e34\u5e8a\u524d\u7814\u7a76\u7684\u6458\u8981\u4fe1\u606f\u5982\u4e0b\uff1a Olverembatinib (HQP1351) in combination with lisaftoclax (APG-2575) overcomes venetoclax resistance in preclinical models of acute myeloid leukemia (AML) \u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408APG-2575\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u7ef4\u5948\u514b\u62c9\u8010\u836f \u6458\u8981\u7f16\u53f7\uff1a5652\u5206\u4f1a\u573a\u7c7b\u522b\uff1a\u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5\u5206\u4f1a\u573a\u6807\u9898\uff1a\u65b0\u578b\u6297\u80bf\u7624\u836f\u72693\u5c55\u793a\u65f6\u95f4\uff1a \uff08\u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff092025\u5e744\u670829\u65e5\uff0c\u5468\u4e8c\uff0c\u4e0b\u534814:00 &#8211; 17:00 \uff08\u5317\u4eac\u65f6\u95f4\uff092025\u5e744\u670830\u65e5\uff0c\u5468\u4e09\uff0c\u51cc\u66683:00 \u2013 6:00 Effects of olverembatinib (HQP1351) in combination with BCL-2 inhibitor lisaftoclax (APG-2575) in T-cell [&hellip;]","og_url":"https:\/\/moneycompass.com.my\/cn\/\u3010aacr-2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\/","og_site_name":"Money Compass CN","article_published_time":"2025-03-26T02:03:00+00:00","og_image":[{"width":144,"height":28,"url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/03\/Ascentage_Pharma_Logo-PpD9vJ.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/","url":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/","name":"\u3010AACR 2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e94\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55 - Money Compass CN","isPartOf":{"@id":"https:\/\/moneycompass.com.my\/cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#primaryimage"},"image":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#primaryimage"},"thumbnailUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/03\/Ascentage_Pharma_Logo-PpD9vJ.jpeg","datePublished":"2025-03-26T02:03:00+00:00","dateModified":"2025-03-26T02:03:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#primaryimage","url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/03\/Ascentage_Pharma_Logo-PpD9vJ.jpeg","contentUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/03\/Ascentage_Pharma_Logo-PpD9vJ.jpeg","width":144,"height":28},{"@type":"BreadcrumbList","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%90aacr-2025%e3%80%91%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82025%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%e5%b9%b4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/moneycompass.com.my\/cn\/"},{"@type":"ListItem","position":2,"name":"\u3010AACR 2025\u3011\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282025\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e94\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55"}]},{"@type":"WebSite","@id":"https:\/\/moneycompass.com.my\/cn\/#website","url":"https:\/\/moneycompass.com.my\/cn\/","name":"Money Compass CN","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/8978"}],"collection":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/comments?post=8978"}],"version-history":[{"count":0,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/8978\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media\/8979"}],"wp:attachment":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media?parent=8978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/categories?post=8978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/tags?post=8978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}